Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Ahn

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Cold Spring Harbor Molecular Case Studies|April 3, 2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancersAlexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.
JTO Clinical and Research Reports|January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> MutationsKathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
JAMA Oncology|May 29, 2020
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label TrialHelena A Yu, Adam J Schoenfeld, Alex Makhnin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Cold Spring Harbor Molecular Case Studies|April 3, 2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancersAlexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.
JTO Clinical and Research Reports|January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> MutationsKathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
JAMA Oncology|May 29, 2020
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label TrialHelena A Yu, Adam J Schoenfeld, Alex Makhnin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.
Pageof 2